Daniel Silberschmidt
5 Papers
86 Citations
Daniel Silberschmidt is an academic researcher. The author has contributed to research in topics: Cancer & Li–Fraumeni syndrome. The author has an hindex of 3, co-authored 5 publications.
Chat about Author
Papers
Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer
Oriol Arqués,Irene Chicote,Isabel Puig,Stephan P. Tenbaum,Guillem Argiles,Rodrigo Dienstmann,Rodrigo Dienstmann,Natalia Fernandez,Ginevra Caratu,Judit Matito,Daniel Silberschmidt,Jordi Rodon,Stefania Landolfi,Aleix Prat,Eloy Espin,Ramón Charco,Paolo Nuciforo,Ana Vivancos,Wenlin Shao,Josep Tabernero,Hector G. Palmer +20 more
TL;DR: Investigation of Wnt-mediated resistance in patients treated with PI3K or AKT inhibitors in clinical trials and evaluation of the efficacy of a new Wnt/tankyrase inhibitor, NVP-TNKS656, to overcome such resistance finds high nuclear β-catenin content independently predicts resistance to PI3k and AKT inhibitor-resistant cells.
165
Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel HER2V659E Mutation
Violeta Serra,Ana Vivancos,Xose S. Puente,Enriqueta Felip,Daniel Silberschmidt,Ginevra Caratu,Josep Lluis Parra,Leticia De Mattos-Arruda,Judit Grueso,Javier Hernández-Losa,Joaquín Arribas,Ludmila Prudkin,Paolo Nuciforo,Maurizio Scaltriti,Joan Seoane,José Baselga +15 more
TL;DR: In this article, the authors reported the molecular characterization and clinical response to a lapatinib-based therapy for the tumors of a Li-Fraumeni patient showing prevalence of HER2 and EGFR genomic alterations.
51
Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel
Violeta Serra,Ana Vivancos,Xose S. Puente,Enriqueta Felip,Daniel Silberschmidt,Ginevra Caratu,Josep-Lluís Parra,Leticia De Mattos-Arruda,Judit Grueso,Javier Hernández-Losa,Joaquín Arribas,Ludmila Prudkin,Paolo Nuciforo,Maurizio Scaltriti,Joan Seoane,José Baselga +15 more
- 01 Jan 2013
TL;DR: The molecular characterization and clinical response to a lapatinib-based therapy for the tumors of a Li-Fraumeni patient showing prevalence of HER2 and EGFR genomic alterations is reported.
41
Abstract C114: Clinical response to a lapatinib-based therapy of a Li-Fraumeni Syndrome patient with a novel HER2-V659E mutation.
Violeta Serra,Ana Vivancos,Xose S. Puente,Enriqueta Felip,Daniel Silberschmidt,Ginevra Caratu,Josep-Lluís Parra,Leticia De Mattos-Arruda,Judit Grueso,Javier Hernández-Losa,Joaquín Arribas,Ludmila Prudkin,Paolo Nuciforo,Maurizio Scaltriti,Joan Seoane,José Baselga +15 more
TL;DR: Following the identification of HER2-activating events in the most recent lung carcinoma and in circulating tumor cells, this work treated the reminiscent metastatic lesions with a lapatinib-based therapy and a clinical response both symptomatic and radiologic was achieved.
1
Syndrome patient with a novel HER2-V659E mutation
Violeta Serra,Ana Vivancos,Xose S. Puente,Enriqueta Felip,Daniel Silberschmidt,Ginevra Caratu,Josep-Lluís Parra,Leticia De Mattos-Arruda,Judit Grueso,Joaquín Arribas,Ludmila Prudkin,Paolo Nuciforo,Joan Seoane,José Baselga +13 more
- 01 Jan 2013
TL;DR: Serra et al. as discussed by the authors treated the reminiscent metastatic lesions with a lapatinib-based therapy and achieved a clinical response both symptomatic and radiologic was achieved in the laboratory.